Serge Leger

Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist.

A. Ford-hutchinson, J. Gauthier, S. Léger, 1989, Canadian journal of physiology and pharmacology.

Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein.

P. Prasit, Z. Wang, S. Charleson, 1994, European journal of pharmacology.

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

D. Riendeau, D. Denis, P. Prasit, 1992, Canadian journal of physiology and pharmacology.

Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

P. Prasit, S. Charleson, J. Evans, 1992, Molecular pharmacology.

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

D. Denis, C. Chan, S. Charleson, 1989, Canadian journal of physiology and pharmacology.